38 results
8-K
EX-99.2
RETA
Reata Pharmaceuticals Inc
10 May 23
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial
6:45am
, pregabalin, gabapentin) Must not have achieved adequate pain control upon entry with NPRS pain intensity score ≥ 4 on a 0-10 point scale at screening … Primary endpoint: Change in average pain intensity assessed by NPRS at Week 12 Plan to initiate the study in Q3 2023
Bardoxolone Update
AYAME
8-K
EX-99.1
tzwbc91p
11 Jan 21
Regulation FD Disclosure
6:30am
424B5
crxtg4mzoljk 2uvdti8
3 Dec 20
Prospectus supplement for primary offering
4:41pm
424B5
782 qylrpnzsa0yh59
1 Dec 20
Prospectus supplement for primary offering
4:17pm
8-K
EX-99.1
8hh2nzxuhsp0 sx9f
9 Nov 20
Vinny Jindal; Reata Pharmaceuticals Inc.; VP of Strategy
5:30pm
8-K
EX-99.2
hbvt21ef w3
9 Nov 20
Reported positive year 2 data from the pivotal CARDINAL study of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome
6:51am
424B5
646c5cbymc5
14 Nov 19
Prospectus supplement for primary offering
4:36pm
424B5
d55cs
12 Nov 19
Prospectus supplement for primary offering
5:15pm